{
  "ticker": "RCE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975617",
  "id": "02975617",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1818",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mdm8ssjbt16s.pdf",
  "summary": "### **Material Information Summary**  \n*(Quarterly Report - Appendix 4C)*  \n\n#### **Operational Highlights:**  \n- **Phase 3 Clinical Trial Progress:** Expanded sites in Indonesia for Diabetic Foot Infections (DFI) trial.  \n- **Phase 2 Trial Expansion:** Additional approval for RECCE\u00ae 327 Gel in Diabetic Foot Ulcer patients.  \n- **USAMRIID Partnership:** CRADA signed with US Army for biodefense pathogen research.  \n- **China Patent Accepted:** Expiry 2041; strengthens IP portfolio.  \n\n#### **Financial Highlights:**  \n- **Closing Cash Balance:** **A$10.53 million** (up from A$0.2M last quarter).  \n- **Net Operating Cash Outflow:** **A$10.81M** (R&D: A$8.8M).  \n- **Capital Raised:** **A$15.8M** (placement to existing shareholders).  \n- **Debt Facility:** **A$30.55M** secured (A$11.49M drawn).  \n- **Government Rebates:** A$271,987 (Canada) + A$8.5M (Australia, expected Nov-2025).  \n\n#### **Funding Runway:**  \n- **Total Available Funding:** ~A$39.63M (cash + undrawn debt + expected rebates).  \n\n*Omitted: Non-material operational details, director fees, and standard disclosures.*",
  "usage": {
    "prompt_tokens": 4849,
    "completion_tokens": 303,
    "total_tokens": 5152,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T08:43:25.835052"
}